Results 161 to 170 of about 19,211 (198)

CATALYTIC ROLES OF CYP2C9 AND ITS VARIANTS (CYP2C9*2 AND CYP2C9*3) IN LORNOXICAM 5′-HYDROXYLATION

Drug Metabolism and Disposition, 2004
The effects of allelic variants of CYP2C9 (CYP2C9*2 and CYP2C9*3) on lornoxicam 5'-hydroxylation were studied using the corresponding variant protein expressed in baculovirus-infected insect cells and human liver microsomes of known genotypes of CYP2C9.
Izumi, Iida, Atsunori, Miyata, Masayuki, Arai, Mitsuyo, Hirota, Masayuki, Akimoto, Shohei, Higuchi, Kaoru, Kobayashi, Kan, Chiba   +7 more
openaire   +2 more sources

Identification and Functional Assessment of a New CYP2C9 Allelic Variant CYP2C9*59

Drug Metabolism and Disposition, 2015
CYP2C9, one of the most important drug-metabolizing enzymes, is responsible for metabolizing approximately 15% of clinically important drugs, including warfarin, diclofenac, and losartan. Similar to other CYP members, human CYP2C9 exhibits marked genetic polymorphisms among individuals of different ethnicities. In this study, a novel missense mutation (
Da-Peng, Dai, Shuang-Hu, Wang, Chuan-Bao, Li, Pei-Wu, Geng, Jie, Cai, Hao, Wang, Guo-Xin, Hu, Jian-Ping, Cai   +7 more
openaire   +2 more sources

Polymorphic Variants (CYP2C9*3 and CYP2C9*5) and the F114L Active Site Mutation of CYP2C9: Effect on Atypical Kinetic Metabolism Profiles

Drug Metabolism and Disposition, 2002
CYP2C9 wild-type protein has been shown to exhibit atypical kinetic profiles of metabolism that may affect in vitro-in vivo predictions made during the drug development process. Previous work suggests a substrate-dependent effect of polymorphic variants of CYP2C9 on the rate of metabolism; however, it is hypothesized that these active site amino acid ...
Timothy S, Tracy, J Matthew, Hutzler, Robert L, Haining, Allan E, Rettie, Matthew A, Hummel, Leslie J, Dickmann   +5 more
openaire   +2 more sources

Prevalence of CYP2C9 polymorphisms in the south of EuropePrevalence of CYP2C9 polymorphisms in Europe

2012
Peer ...
Sánchez-Diz, Paula, Velasco, Eladio
openaire   +2 more sources

CYP2C9*3/*3 : rijetki genotip CYP2C9

2003
Enzim CYP2C9 je odgovoran za metabolizam S-varfarina. Uz divlji tip alela CYP2C9*1, najčešće aleli u bjelačkoj populaciji su CYP2C9*2 i CYP2C9*3. Cilj rada bio je ispitivanje povezanosti polimorfizma CYP2C9 s varijabilnošću doze varfarina u bolesnika na antikoagulantnoj terapiji.
Miškulin, Ivica, Štefanović, Mario, Topić, Elizabeta   +2 more
openaire   +2 more sources

Allele frequency distribution of CYP2C9*2 and CYP2C9*3 polymorphisms in six Mexican populations

Gene, 2013
Allele frequency differences of functional CYP2C9 polymorphisms are responsible for some of the variation in drug response observed in human populations. The most relevant CYP2C9 functional variants are CYP2C9*2 (rs1799853) and CYP2C9 3 (rs1057910). These polymorphisms show variation in allele frequencies among different population groups.
Osvaldo D, Castelán-Martínez, Carlos, Hoyo-Vadillo, Emmanuel, Sandoval-García, Lucila, Sandoval-Ramírez, Miriam, González-Ibarra, Gloria, Solano-Solano, Rita A, Gómez-Díaz, Esteban J, Parra, Miguel, Cruz, Adán, Valladares-Salgado   +9 more
openaire   +2 more sources

Identification and Functional Characterization of a New CYP2C9 Variant (CYP2C9*5) Expressed among African Americans

Molecular Pharmacology, 2001
CYP2C9 is a polymorphic gene for which there are four known allelic variants; CYP2C9*1, CYP2C9*2, CYP2C9*3, and CYP2C9*4. In the present study, DNA from 140 European Americans and 120 African Americans was examined by single-strand conformational polymorphism and restriction fragment length polymorphism analyses, resulting in the identification of a ...
L J, Dickmann, A E, Rettie, M B, Kneller, R B, Kim, A J, Wood, C M, Stein, G R, Wilkinson, U I, Schwarz   +7 more
openaire   +2 more sources

Significance of CYP2C9 genetic polymorphism in inhibitory effect of Δ9-tetrahydrocannabinol on CYP2C9 activity

Forensic Toxicology, 2012
We recently reported that Δ9-tetrahydrocannabinol (Δ9-THC), the primary psychoactive constituent in marijuana, potently inhibits the catalytic activity of cytochrome P450 (CYP) 2C9.1, a wild-type variant. However, effects of CYP2C9 genetic polymorphisms on the inhibitory potency of Δ9-THC have not been investigated.
Satoshi Yamaori, Mika Kushihara, Kyoko Koeda, Ikuo Yamamoto, Kazuhito Watanabe   +4 more
openaire   +1 more source

Mechanism-based inactivation of CYP2C9 by linderane

Xenobiotica, 2015
1. Linderane (LDR), a furan-containing sesquiterpenoid, is found in Lindera aggregata (Sims) Kosterm, a common traditional Chinese herbal medicine. We thoroughly studied the irreversible inhibitory effect of LDR on cytochrome P450 2C9 (CYP2C9). 2. LDR caused a time- and concentration-dependent inactivation of CYP2C9.
Hui, Wang, Kai, Wang, Xu, Mao, Qingqing, Zhang, Tong, Yao, Ying, Peng, Jiang, Zheng   +6 more
openaire   +2 more sources

Mechanism of CYP2C9 Inhibition by Flavones and Flavonols

Drug Metabolism and Disposition, 2009
This article describes an in vitro investigation of the inhibition of cytochrome P450 (P450) 2C9 by a series of flavonoids made up of flavones (flavone, 6-hydroxyflavone, 7-hydroxyflavone, chrysin, baicalein, apigenin, luteolin, scutellarein, and wogonin) and flavonols (galangin, fisetin, kaempferol, morin, and quercetin). With the exception of flavone,
Dayong, Si, Ying, Wang, Yi-Han, Zhou, Yingjie, Guo, Juan, Wang, Hui, Zhou, Ze-Sheng, Li, J Paul, Fawcett   +7 more
openaire   +2 more sources